NCT00071708Approved For Marketing不适用
Open Label Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 1
研究概览
简要总结
The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is not available.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and Female outpatients at least 18 years of age who have previously participated in a Lilly sponsored neuroscience duloxetine clinical trial
- •All females must have a negative urine pregnancy test at visit
- •Females of childbearing potential must agree to utilize medically acceptable and reliable means of birth control.
- •Must sign the informed consent document
排除标准
- •Have received treatment within the last 30 days with a drug except for duloxetine that has not received regulatory approval for any indication at the time of study entry
- •In the opinion of the investigator, patient judged to be at serious suicidal risk.
- •Serious or unstable hepatic or renal function or unstable narrow angle glaucoma.
- •Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days prior to visit 1 or potential to use a MAOI during the study or within 5 days of discontinuation of study drug.
- •Any patient who previously experienced a serious adverse event while taking duloxetine unless approved by the Lilly Physician
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety DisorderIrritable Bowel SyndromeGeneralized Anxiety DisorderNCT00961298West Penn Allegheny Health System17
已完成
3 期
Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major DepressionMajor Depressive DisorderNCT00042562Eli Lilly and Company
已完成
3 期
Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and PainPainDepressionNCT00036335Eli Lilly and Company286
已完成
3 期
A Study of Duloxetine in FibromyalgiaFibromyalgiaNCT01552057Eli Lilly and Company393
已完成
3 期
An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)Osteoarthritis of the KneeNCT02335346Eli Lilly and Company93